Hisun Pharmaceutical: The new indication for the innovative drug HSK39297 tablet has been approved for clinical trials.

Hisilicon announced that it has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. Its independently developed innovative drug HSK39297 tablets for age-related macular degeneration have been approved for domestic production drug registration clinical trials. In 2015, the prevalence of AMD in China was approximately 5.2%, with nearly 26.65 million patients, and it is estimated that by 2040, nearly 300 million people will be affected. Currently, there are limitations in AMD treatment drugs, but this drug has clear targets, definite efficacy, and good safety, offering hope in solving clinical medication challenges. However, the risks of innovative drug research and development are high, and the company will disclose progress in a timely manner.